AH
Uploaded byAishwarya Hajare
PPTX, PDF21,174 views

DRUG INDUCED GINGIVAL ENLARGMENT (DIGO)

The document provides a comprehensive overview of drug-induced gingival enlargement, including its classification, associated drugs (such as anticonvulsants and calcium channel blockers), and clinical manifestations. It details the prevalence, risk factors, management strategies, and various indices used to assess gingival enlargement. Additionally, the document discusses the pathogenesis and histopathological features of gingival overgrowth due to drugs, emphasizing the complexity of this condition across different patient demographics.

Embed presentation

Downloaded 144 times
DRUG INDUCED GINGIVAL ENLARGEMENT 1
1. Introduction 2. Classification of gingival enlargement 3. Indices for gingival enlargement 4. Drugs associated with gingival enlargement o Anticonvulsants o Immunosuppressants o Calcium Channel blockers o Miscellaneous 8. Prevalence of drugs causing gingival enlargement 9. Clinical manifestations and Histopathologic features 10. Pathogenesis of Drug induced gingival enlargement 11. Risk factors for Drug induced gingival enlargement 12. Management 13. References 2
Coral PinkScalloped & Knife edged Surface Texture StippledFirm & resilient consistency Size : Cellular + Intercellular + Vasculature Interdental Papilla Anterior – Pyramidal Posterior – Tent shaped Gingiva in health….. 3
INCREASE IN SIZE OF GINGIVA INFLAMMATORY TYPE Increased cells Decreased fibers NON - INFLAMMATORY TYPE Increased fibers Decreased cells 4
REASONS FOR INCREASE IN SIZE OF GINGIVA Accumulation of: Products of inflammation Increase in: Cellular + fibrous + ground substance 5
Various terms used previously Gingival Hyperplasia Gingival Hypertrophy Fibrous gingival Hyperplasia Gingival Overgrowth To denote excessive gingival proliferation secondary to drugs Gingival Enlargement Preferred term 6
7 SEQUELAE OF GINGIVAL OVERGROWTH Aesthetic changes Difficulty in maintaining good oral hygiene Clinical symptoms such as pain Speech disturbances Abnormal tooth movement Dental occlusion problem Enhanced risk of caries & periodontitis Brunnet et al 1996
8 CLASSIFICATION OF GINGIVAL ENLARGEMENT
9 • Acute • Chronic Inflammatory enlargement • Drug induced • Idiopathic Fibrotic enlargement • Fibrotic + InflammatoryCombined enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement OLDERCLASSIFICATION According to etiologic factors & pathologic changes
10 • Acute • Chronic Inflammatory enlargement Drug induced enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement MODIFIEDCLASSIFICATION According to etiology
SHAFER’S CLASSIFICATION 11 Inflammatory gingival hyperplasia Non inflammatory (fibrous) gingival hyperplasia Combination of inflammatory and fibrous hyperplasia Shafer WG, Hine M, Levy B. Shafer’s textbook of oral pathology. Elsevier. New Delhi. 5th ed, 2006.
12 BASED ON DISTRIBUTION Localized: Limited to the gingiva adjacent to single or group of teeth Generalized: Involving gingiva throughout the mouth BASED ON LOCATION Marginal: Confined to marginal gingiva Papillary: Confined to interdental papilla Diffuse: Involving the marginal, attached gingiva and papillae Discrete : An isolated sessile or pedunculated, tumour like enlargement
13 INDICES FOR GINGIVAL ENLARGEMENT
• Kimbal et al, 1939 • Harris & Ewall, 1942 • Robinson et al, 1945 • Babcock and Nelson, 1964 • Angelopoulos & Goaz et al, 1972 • Conrad et al, 1974 • Barak et al, 1985 • Seymour et al, 1985 • Daley et al, 1986 • Friskopp & Klintman et al, 1986 • Mc Gaw index, 1987 • Kitaneara et al, 1990 • Miller and Damm index, 1992 • King et al, 1993 • Bokenkamp et al, 1994 • Miranda et al, 1998 • New index for DIGO (Ingles et al), 1999 • Modified Harris & Ewait index, (Prasad et al, 2002) VARIOUS INDICES USED TO MEASURE GINGIVAL ENLARGEMENT 14
BASED ON CLINICAL APPEARANCE 1. Babcock and Nelson, 1964 GRADING OF GINGIVAL ENLARGEMENT 15 Mild No gingival enlargement or a minimal enlargement. Moderate Slight but definitive gingival enlargement, not interfering with function. Severe Gingival enlargement interfering with the function.
2. Angelopolus & Goaz –1972 Nery et al (1995) modified by adding interproximal area. 16 Grade 0 No hyperplasia Grade 1 Hyperplasia covering cervical 3rd of anatomic crown Grade 2 Hyperplastic gingiva extending the middle 3rd of anatomic crown of teeth Grade 3 Hyperplastic gingiva covering > 2/3rd of crown of anterior tooth.
17 Grade 0 No signs of inflammation Grade 1 GE confined to interdental papilla Grade 2 Enlargement involves papilla &marginal gingiva. Grade 3 Enlargement covers three quarters or more of crown. Grade 0 No signs of gingival enlargement. Grade I Enlargement confined to interdental papilla. Grade II Enlargement involves papilla and marginal gingiva Grade III Enlargement covers three quarter or more of the crown 3. Mc Gaw et al (1987) 4. Bokenkamp et al, 1994
BASED ON HISTOPATHOLOGICAL EXAMINATION Barak et al (1985) 18 Grade 1 Normal width of epithelium - 0.30 to 0.50 mm Grade 2 Slight hyperplasia - 0.50 to 1.5 mm Grade 3 moderate hyperplasia - 1.50 to 3.0 mm Grade 4 severe hyperplasia - 3 to 4 mm
BASED ON ASSESSMENT OF PLASTER STUDY CASTS Seymour et al –1985 Included both gingival thickening and encroachment of gingival tissues on the adjacent crowns. 19 Grade 0 Normal Grade 1 Thickening from normal upto 2mm Grade 2 Thickening >2mm Criteria for assessing gingival thickness in a labio-lingual direction for a gingival unit. Criteria for assessing gingival encroachment on adjacent tooth surfaces for a gingival unit. (MGL = Mucogingival line).
BASED ON PHOTOGRAPHIC ANALYSIS Ellis & Seymour, 1993 20 0 No encroachment of interdental papilla onto tooth surface. 1 Mild encroachment of interdental papilla, producing a blunted appearance to papilla tip. 2 Moderate encroachment, involving lateral spread of papilla across buccal tooth surface of less than one quarter tooth width. 3 Marked encroachment of papilla, i.e., more than 1/4 tooth width. Loss of normal papilla form.
INDICES FOR DRUG INDUCED GINGIVAL ENLARGEMENT 21 0 No overgrowth 1 Early changes detectable, without encroachment on the tooth 2 Moderate changes, with increased enlargement of the interdental papillae and slight encroachment of the gingival tissues onto the tooth surfaces 3 Marked changes with obvious encroachment of the gingival tissues onto the tooth surfaces.
Grade 0 Grade 1 NEW CLINICAL INDEX FOR DRUG INDUCED GINGIVAL OVERGROWTH 22 1 No overgrowth; firm adaptation of the attached gingiva to the underlying alveolar bone. 2 There is slight stippling; there is no granular appearance or a slightly granular appearance. 3 A knife-edged papilla is present toward the occlusal surface. 4 There is no increase in density or size of the gingiva. 1 Early overgrowth, as evidenced by an increase in density of the gingiva with marked stippling and granular appearance. 2 The tip of the papilla is rounded. 3 The probing depth is less than or equal to 3 mm.
Grade 2 Grade 3 23 1 Moderate overgrowth, manifested by an increase in the size of the papilla and/or rolled gingival margins. 2 The contour of the gingival margin is still concave or straight. 3 Gingival enlargement has a bucco-lingual dimension of up to 2 mm, measured from the tip of the papilla outward. 4 The probing depth is equal to or less than 6 mm. 5 The papilla is somewhat retractable. 1 Marked overgrowth, represented by encroachment of the gingiva onto the clinical crown. 2 The contour of the gingival margin is convex rather than concave. 3 Gingival enlargement has a bucco-lingual dimension of approximately 3 mm or more, measured from the tip of the papilla outward. 4 The probing depth is greater than 6 mm. 5 The papilla is clearly retractable.
Grade 4 24 1 Severe overgrowth, characterized by a profound thickening of the gingiva 2 A large percentage of the clinical crown is covered. 3 Same as for grade 3: The papilla is retractable, the probing depth is greater than 6 mm, and the buccolingually dimension is approximately 3 mm.
DRUGS ASSOCIATED WITH GINGIVAL ENLARGEMENT 25 Anticonvulsants Miscellaneous Calcium channel blockers Immunosuppressants
PREVALENCE RATE 26 Phenytoin 50%Cyclosporine 30% Nifedipine 20% Drugs modify the inflammatory and immunologic responses of the host to plaque Goldman et al Clinically & histologically gingival overgrowth induced by different drugs, are virtually indistinguishable. Wysocki et al 1983, Tyldesley & Rotter 1984
ANTICONVULSANTS 27 HYDANTOINS SUCCINIMIDES VALPROIC ACID Ethotoin (Peganone®) Ethosuximide (Zarontin®) Depakene (Depakote®) Mephenytoin (Mesantoin®) Methsuximide (Celontin®) Phenytoin (Dilantin®) Phensuximide (Milontin®) Kimball 1939 - First to report gingival enlargement with chronic usage of Phenytoin. Children & Adolescents Adults Anterior region Posterior Region
28 Uses Threshold plasma concentration Incidence Active metabolite Progression Epilepsy – generalized tonic-clonic seizures, partial seizures. 10-20µg/ml (Rees et al, 1993) 0 - 84.5%, Average 50% (Angelopoulo s et al) 5- parahydroxyp henyl-5- phenylhydant oin Onset – after one month of use. Trigeminal & related neuralgias ↑ prevalence in children (Dahllof & Modeer) Maximum severity reached: 12-18 months Cardiac arrhythmias Decreased rate observed: in the second year Adverse drug effects 1. Nausea, Vomitting, Epigastric pain & anorexia. 2. Nystgmus, Diplopia, Ataxia. 3. Gingival hyperplasia (common in children on prolonged use). 4. Peripheral neuropathy. 5. Endocrine – i) Hirsuitism, acne, coarsening of facial features ii) Hyperglycemia, iii)Osteomalacia, hypocalcaemia 6. Hypersensitivity reactions 7. Megaloblastic Anaemia 8. Teratogenicity PHENYTOIN
29 Immunosuppressants Cyclosporin A Tacrolimus Cyclosporin – A First isolated in Switzerland – 1970, Jean Borel First case reported by - Rateitschak Pluss,1983 Suppress some humoral immunity (B lymphocytes) and to a much greater extent, cell-mediated immunity (T lymphocytes) such as allograft rejection, delayed hypersensitivity. Inhibits IL-2 synthesis and release.
30 IMMUNOSUPPRESSANTS Uses Threshold plasma concentration Incidence Active metabolite Progression Immunosuppressant in transplant rejection (kidney, heart, liver transplant) > 400ng/ml 25% of renal transplant cases OL-17 Progressive enlargement occurs over several months Treatment of rheumatoid arthritis, psoriasis 38% of Cardiac transplants Reaches peak after one year of treatment Severe atopic dermatitis, chronic autoimmune urticaria 37% of Liver transplants Graft-versus Host reaction Adverse drug effects 1. Nephrotoxicity 2. Hepatotoxicity 3. Anorexia 4. Gum hypertrophy 5. Increased susceptibility to infections Friskopp & Klintmalm (1986)- Enlargement restricted to keratinized gingiva but can extend coronally. Absent in edentulous areas.
CALCIUM CHANNEL BLOCKERS 31 Dihydropyridine derivatives Benzothiazine derivatives Phenylalkylamine derivatives Amlodipine (Lotrel®, Norvasc ®) Diltiazem (Cardizem®, Dilacor®, Tiazac®) Verapamil HCL (Calan®, Isoptin®, Verelan®) Felodipine (Plendil®) Nifedipine (Adalat®, Procardia ®) Nimodipine (Nimotop®) Lederman et al, 1984 - First to report gingival enlargement with chronic usage of Nifedipine
32 Uses Pulmonary Hypertension Raynaud’s phenomena Threshold plasma concentration 800ng/ml Resulted in gingival overgrowth (rat model) Nishikawa et al. 1995 Incidence 15% - 84% Avg: 42.5% Severity Increases the risk of periodontal destruction in patients with diabetes mellitus type 2 Does not appear to affect edentulous areas, Nifedipine induced gingival enlargement is seen around implants. (Silverstein et al 1995) Adverse drug effects 1. Cardiac depression 2. Facial flushing 3. Dizziness 4. Headache 5. Edema 6. Gingival enlargement
33 MISCELLANEOUS Prednisone Prednisolone Valsartan Atenolol Paracetamol Lysine acetylsalicylate Acebutalol Metoprolol Isosorbide dinitrate Trinitrine Spironolactone Allopurinol Oral contraceptives Containing : Ethinylestradiol Levonorgestrel Desogestrel
34 CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT
CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT • Growth starts as: o A painless beadlike enlargement of the interdental papilla o Extends to facial & lingual gingival margins. • On progression: o Marginal & papillary enlargements unite o Develop into massive tissue fold covering large part of crown o Interfere with occlusion • When uncomplicated by inflammation: o Lesion is mulberry shaped o Firm and resilient o Pale pink o Minutely lobulated surface o No tendency to bleed 35
• Enlargement characteristically appears to: o Project from beneath the gingival margin o From which it is separated by a linear groove. • Enlargement is usually generalized • More severe in maxillary & mandibular anterior regions. • Occurs in areas in which teeth are present & not in edentulous spaces. • Plaque control becomes difficult due to the enlargement Resulting Secondary inflammatory process (Further complicates the gingival overgrowth caused by the drug) 36
Resultant enlargement Increase in size caused by the drug + plaque induced inflammation. • Drug-induced enlargement may occur in mouths: o With little or no plaque o May be absent in mouths with abundant deposits. • Enlargement is: o Chronic o Slowly increases in size. o When surgically removed, it recurs. o Spontaneous disappearance occurs within a few months after discontinuation of the drug. 37
HISTOPATHOLOGY • Pronounced hyperplasia of the connective tissue & epithelium. • Acanthosis of the epithelium. • Elongated rete pegs extending deep into the connective tissue. • Densely arranged collagen bundles. • Increase in the number of fibroblasts & new blood vessels. • Abundance of amorphous ground substance. Mariani et al 38
39 CLINICAL AND HISTOPATHOLOGIC FEATURES OF VARIOUS DRUGS
DRUGS CLINICAL FEATURES HISTOPATHOLOGY PHENYTOIN • Granular or pebbly surface of affected tissues enlarged papillae extending facially &/or lingually. • Formation of pseudoclefts due to confluence of enlarged papillae (Hallmon & Rossmann) • Florid overgrowth of affected papillae. • Rare cases - observed in edentulous patients & beneath pontics of FPDs (McCord J, Sloan P, 1992) • Fibroblast to collagen ratio equal to that of normal gingiva from normal individuals. Florid overgrowth of affected papillae and presence of pseudoclefts resulting from overlapping of adjacent marginal gingiva and papillary confluence after long term Phenytoin use. 40 DRUGS CLINICAL FEATURES HISTOPATHOLOGY CYCLOSPORIN A • Affects children more frequently • Enlarged gingival tissues are soft • Extremely fragile • Red or bluish red • Bleed easily upon probing. • Restricted to keratinized gingiva only, so no interference with occlusion, mastication or speech. (Friskopp and Klintmalm, 1996) • More hyperemic than phenytoin induced enlargement. (Seymour & Jacobs, 1992) • Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells . NIFEDIPINE • Enlarged interdental papilla. • Lobulated /nodular morphology. • 10 fold increase in epithelial width. • Increase capillary vascularity • Slight perivascular inflammation. CYCLOSPORINE INDUCED GINGIVAL OVERGROWTH
HISTOPATHOLOGY OF DRUG–INDUCEDGINGIVALENLARGEMENT PHENYTOIN NIFEDIPINE CYCLOSPORIN A Fibroblast to collagen ratio in mature lesion is equal to that of normal gingiva from normal individuals Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells. • Ten fold increase in epithelial width. • Increased capillary vascularity and slight perivascular inflammation. 41
42 PATHOGENESIS OF DRUG INDUCED GINGIVAL ENLARGEMENT
PATHOGENESIS OF DIGO 43 Pathogenesis Increased collagen synthesis Decreased collagen degradation - Extracellular pathway - Intracellular pathway Combination
DRUG METABOLITES (Phenytoin, Nifedipine, Cyclosporin) Increased collagen production Increased extracellular matrix synthesis T- lymphocytes TH2 response IL-13, 1L4 Macrophages TGF-β CTGF FGF-2 PDGF 44 INCREASED COLLAGEN SYNTHESIS FIBROBLASTS Proliferation of highly active fibroblasts
45 DECREASED COLLAGEN DEGRADATION Drugs associated with gingival enlargement (Anticonvulsants, Immunosuppressants, CCB, others) Disturbance in calcium homeostasis Decreased influx of Ca2+ into fibroblast Decreased uptake of Ca2+ dependant folic acid by fibroblasts Decreased production of active collagenase Increased expression of TIMP Decreased MMP 1, 2 & 3 mediated collagen degradation
Waxman et al, 1970 Long term phenytoin therapy Low serum level of folic acid Drug metabolite reduces the absorption from GIT Blocks the transport across intestinal epithelium Decreased folate reductase Impaired maturation of epithelium Connective tissue susceptible to inflammation 46
Decreased collagen phagocytosis Phenytoin induced Reduced α2β1 Integrin expression on fibroblasts Decreased adhesion of Type 1 Collagen with Fibroblast Decreased Endocytosis Decreased phagocytosis of Type 1 collagen Fibroblast Apoptosis Phenytoin induced Decreased Fibroblast apoptosis Contribute to fibrosis Increased number of fibroblasts Extracellular matrix accumulation Kantarci P A, 2007 47 INTRACELLULAR PATHWAY α 2β1 receptors Receptors UPARAP/ENDO 180 – One of the main receptors responsible for collagen phagocytosis. Not enough evidence to substantiate the role of this receptor.
Joice et al: Phenytoin Induced Gingival overgrowth: A review of the cellular, molecular and inflammatory features 10.5402/2011/497850 Modification of immune cells by drug metabolites Imbalance in production of cytokines and other mediators Increased TGFβ1, FGF-2 and others TGFβ1 Increases synthesis and deposit of collagen. Regulation of TIMP. Reduction of collagen phagocytosis. Myofibroblasts are associated with later stages of tissue turnover. 48
49 RISK FACTORS FOR DRUG INDUCED GINGIVAL ENLARGEMENT
RISK FACTORS FOR DRUG INDUCED GINGIVAL ENLARGEMENT RISK FACTORS 1. Age 2. Genetic factors 3. Pharmacokinetic variables 4. Alterations in the gingival connective tissue 5. Drug induced action on growth factors. UNIFYING HYPOTHESIS Vogel et al discussed first the possible mechanism of pathogenesis that grouped several current hypothesis together. DISSIMILAR DRUGS - SIMILAR EFFECTS Action on Ca2+ & Na+ influx Link between dissimilar drugs causing gingival enlargement 50
51 AGE Fibroblasts in areas of Inflamed gingival tissues Androgen (Testosterone) 5 α- Dihydrotestosterone (5α DHT) Biologically active Stimulation of biosynthetic activity in subpopulation of fibroblasts Increased collagen production Children/Adolescent Increased production of androgen (testosterone) Sooriyamoorthy M, Gower D, Eley BM. Androgen metabolism in gingival hyperplasia induced by Nifedipine and Cyclosporin. JOP. 1990;25:25-30
52 GENETIC PREDISPOSITION PHENYTOIN/CYCLOSPORINE/CCB Altered metabolism of drug Threshold concentration of drug/metabolite Disturbance in calcium homeostasis Decreased Folate Reductase Gingival fibroblasts are activated Decreased collagen breakdown Cytochrome P450 Genotype C807
53 PHARMACOKINETIC VARIABLES Systemic administration of drug Local sequestration Increased concentration in saliva/GCF Threshold concentration Altered fibroblast activity Concomitant Medication: Higher Incidence, Severity & Recurrence rate Phenytoin + Cyclosporin Bokenkamp 1994 Margiotta 1996 Prednisolone & Azathioprine - Combined immunosuppressant action with Phenytoin, Cyclosporin & Calcium channel blockers Degree of salivary Phenytoin & gingival overgrowth Babcock & Nelson1964 Cyclosporin concentration in stimulated saliva & extent of gingival overgrowth Mc Gaw et al 1987 Hefti et al 1994 Assumption: Serum concentration of active drug > gingival enlargement to occur. Threshold differs between: o Individuals o Drug to drug Seymour,1988, 2000 Daley et al1986 Patients exhibiting gingival overgrowth Nifedipine & Amlodipine Conclusions: 1. Can be detected in GCF 2. Significant sequestration of drug Ellis et al. 1992 Seymour et al. 1994 Direct relationship
54 ALTERATION IN CONNECTIVE TISSUE METABOLISM HOMEOSTATIC BALANCE Collagen production Collagen degradation ALTERED METABOLISM Fibroblast heterogeneity Hyperactivity Increased TIMP (Tipton et al, 1991) Decreased/abnormal Collagenase Increased collagen production (Goultchin & Shoskan 1980) Decreased collagen breakdown Acanthosis & accumulation of non collagenous extracellular substances In addition deficiency of Cathepsin B and L together with increased levels of Hexose amine, Hyaluronic acid and total protein content.
55 . PHENYTOIN Responders: Up-regulation of EGF receptor metabolism Non responders: Down-regulation of EGF receptor metabolism Modeer et al 1990 d PDGF secretion from macrophages Dill et al. 1993 Abnormal response to plaque induced inflammatory changes DRUG-INDUCEDACTIONON GROWTH FACTORS
56 MANAGEMENT OF GINGIVAL ENLARGEMENT
MANAGEMENT OF GINGIVAL ENLARGEMENT 57 NON SURGICAL 1. Scaling and Root planing 2. Drug Substitution 3. Antimicrobials 4. Supplements SURGICAL 1. Gingivoplasty 2. Gingivectomy 3. Periodontal flap surgery
58 Mouth wash Chlorhexidine Gluconate – 0.2 % Metronidazole Usage is controversial Increases drug metabolites of Cyclosporin in blood. Adverse drug effects of Cyclosporin Seen Azithromycin Mechanism of Action:  High intracellular accumulation (Azithromycin metabolites): o Endogenous defense cells o Tissues affected by inflammatory changes  Increase phagocytosis of collagen fibres Counter acts Decreasing accumulation of extracellular matrix ANTIBIOTICS Dannewitz B, Proliferation of the gingiva: etiology, risk factors and treatment modalities for gingival enlargement. Perio 2007;4(2):83-92
59 SUBSTITUTE FOR NIFEDIPINE SUBSTITUTE FOR CYCLOSPORIN A SUBSTITUTE FOR PHENYTOIN Isradipine 20 mg BD Tacrolimus (0.15 - 0.20/kg/d) Phenobarbital 60 mg TDS ACE Inhibitors - Captopril 12.5 - 50 mg BD - Enalapril (2.5 - 20 mg OD) Rapamycin Primidone 100 mg TDS Carbamazepine 200 – 400 mg TDS Valproic acid 200 – 500 mg TDS
60 No sufficient data exists to indicate folic acid therapy is beneficial in Phenytoin induced Gingival enlargement PHENYTOIN INDUCED GINGIVAL ENLARGEMENT Therapeutic benefits Inove & Harrison, Prasad et al No therapeutic benefits Brown et al, Majota et al Folic acid therapy
GINGIVECTOMY ELECTROSURGERY LASER CHEMOSURGERY CONVENTIONAL 61
62 1. Text book of Periodontology by Carranza FA. 10th edition 2007. 2. Textbook of Periodontics, Medicine, surgery and Implants by Rose, Mealey, Genco. 2004. 3. Paulo M, Camargo, Philip R, Melnick, Flavia M, Pirih, Takei. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontology 2000, Vol. 27, 2001, 131–138. 4. William W, Hallmon, Jeffrey A, Rossmann. The role of drugs in the pathogenesis of gingival overgrowth: A collective review of current concepts. Periodontology 2000, Vol. 21, 1999, 176-196. 5. Michelle L, Moffitt, David E, Bencivenni, Robert E Cohen. Drug-Induced Gingival Enlargement: An Overview. Compend; CDE 2; 2013, 34: 5.
63 6. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. On the mechanism of DIGH. Oral Pathol Med. 1991; 20:201-9. 7. Nyska A, M. Shemesh, H Tal, Dayan D. Gingival Hyperplasia Induced by Calcium Channel Blockers: Mode of Action. Medical Hypothesis. 1994; 43:115-118. 8. Christina Popova, Antoaneta Mlachkova. Surgical approach to drug - induced 9. gingival enlargement in renal transplant patients: Case report. J of IMAB, 2007, vol. 13, book 2. 10. Arnold D Steinberg. Clinical management of phenytoin-induced gingival overgrowth in handicapped children. Pediatric dentistry. Volume 3, Special Issue. 11. Chae HJ, Ha MS, Yun DH, Chung HT. Mechanism of Cyclosporine-induced Overgrowth in Gingiva. J Dent Res85(6):515-519, 2006.
64 C A S E 1 C A S E 2
65

More Related Content

PPTX
Gingival enlargement
byManishaSinha17
 
PPTX
GINGIVAL ENLARGEMENT+MGMT
byDr Antarleena Sengupta
 
PPTX
Drug induced gingival enlargement.
byGururam MDS
 
PPTX
Gingivalenlargment HOD SIR.pptx
byDentalYoutube
 
PPTX
Gingival enlargement
byMehul Shinde
 
PPT
Gngival enlargement
byParth Thakkar
 
PPTX
GINGIVAL ENLARGEMENT: PART-1 AND PART-2
byDr. Shashi Kiran
 
PPTX
Gingival enlargement
byRiya Shah
 
Gingival enlargement
byManishaSinha17
 
GINGIVAL ENLARGEMENT+MGMT
byDr Antarleena Sengupta
 
Drug induced gingival enlargement.
byGururam MDS
 
Gingivalenlargment HOD SIR.pptx
byDentalYoutube
 
Gingival enlargement
byMehul Shinde
 
Gngival enlargement
byParth Thakkar
 
GINGIVAL ENLARGEMENT: PART-1 AND PART-2
byDr. Shashi Kiran
 
Gingival enlargement
byRiya Shah
 

What's hot

PPTX
Gingival enlargment and its treatment
byNavneet Randhawa
 
PPTX
BLEEDING ON PROBING - PERIODONTICS
byDr. Vishal Gohil
 
PPTX
Aggressive periodontitis
byBinaya Subedi
 
PPTX
Plaque hypothesis ppt
byPerio Files
 
PPTX
Attached gingiva and its significance
byMD Abdul Haleem
 
PPTX
Furcation involvement
byneeti shinde
 
PPSX
Supportive Periodontal Therapy
byJignesh Patel
 
PPTX
Periodontal plastic surgery
byDR. REBICCA RANJIT
 
PPTX
ATTACHED GINGIVA
byDr Mushahida Anjum
 
PPTX
POCKET ELIMINATION
byAnurag Jb
 
PPTX
Periodontal probe
bydebasismitra
 
PPTX
Periodontal flap
byakshay shete
 
PPTX
Furcation involvement
byDr. Mariyam Momin
 
PPTX
Host modulation therapy
byAnkita Dadwal
 
PPTX
Patterns of bone destruction in periodontics
byManeesh Ahammed Syed
 
PPTX
Host modulation
byGanesh Nair
 
PPTX
Trauma from occlusion
byNavneet Randhawa
 
PPTX
Gingival curettage
bymatru seva dental hospital
 
PPT
Dental implants _perio_
byHatem Abouelnasr
 
PPTX
Host Modulation Therapy
byDr.Shraddha Kode
 
Gingival enlargment and its treatment
byNavneet Randhawa
 
BLEEDING ON PROBING - PERIODONTICS
byDr. Vishal Gohil
 
Aggressive periodontitis
byBinaya Subedi
 
Plaque hypothesis ppt
byPerio Files
 
Attached gingiva and its significance
byMD Abdul Haleem
 
Furcation involvement
byneeti shinde
 
Supportive Periodontal Therapy
byJignesh Patel
 
Periodontal plastic surgery
byDR. REBICCA RANJIT
 
ATTACHED GINGIVA
byDr Mushahida Anjum
 
POCKET ELIMINATION
byAnurag Jb
 
Periodontal probe
bydebasismitra
 
Periodontal flap
byakshay shete
 
Furcation involvement
byDr. Mariyam Momin
 
Host modulation therapy
byAnkita Dadwal
 
Patterns of bone destruction in periodontics
byManeesh Ahammed Syed
 
Host modulation
byGanesh Nair
 
Trauma from occlusion
byNavneet Randhawa
 
Gingival curettage
bymatru seva dental hospital
 
Dental implants _perio_
byHatem Abouelnasr
 
Host Modulation Therapy
byDr.Shraddha Kode
 

Similar to DRUG INDUCED GINGIVAL ENLARGMENT (DIGO)

PPTX
Gingival_enlargement_ppt.pptx
bymalti19
 
PPTX
Drug induced gingival enlargement - DIGO
bydivyaguptamds2326
 
PPTX
drug induced gingival enlargement-190530051811 (1).pptx
bydivyaguptamds2326
 
PPTX
Gingival enlargement
byzebazareen
 
PPTX
GINGIVAL_ENLARGEMENT[1].pptx
byveena621629
 
PPTX
Gingival enlrgment
byImran Bhatt
 
PPTX
Gingival enlargement
byKalaivani Gunalan
 
PPTX
Gingival Enlargement
byMaryam Arbab
 
PPT
Gingival Enlargement.ppt
bypayampayamy1
 
PPTX
GINGIVAL-ENLARGEMENT
byPerio Files
 
PPTX
Gingival enlargement
byKirthana MS
 
PPTX
Gingival enlargement
byDr. Varsha Vishwakarma
 
PDF
Gingival Enlargement Periodontology Persentaty
byHome
 
PPT
GINGIVAL ENLARGEMENT Etiology and management
byPriyanka Pai
 
PDF
Lecture 4 Gingival Enlargement disorders
byahmedashraflol85
 
PPT
gingival enlarvhvhnvnhvnvvnvnvhnbgment.ppt
bySamanArshad11
 
PPTX
Gingival Enlargementdental periodontal.pptx
byMohamedYElZahar
 
PPTX
8)GINGIVAL ENLARGEMENT; a disease of the perodontium.pptx
byChukwuenyemBlessing
 
PPTX
Gingival Enlargement in periodontics pptx
bySneha Banerjee
 
PPT
Gingival Enlargement.ppt
bypayampayamy1
 
Gingival_enlargement_ppt.pptx
bymalti19
 
Drug induced gingival enlargement - DIGO
bydivyaguptamds2326
 
drug induced gingival enlargement-190530051811 (1).pptx
bydivyaguptamds2326
 
Gingival enlargement
byzebazareen
 
GINGIVAL_ENLARGEMENT[1].pptx
byveena621629
 
Gingival enlrgment
byImran Bhatt
 
Gingival enlargement
byKalaivani Gunalan
 
Gingival Enlargement
byMaryam Arbab
 
Gingival Enlargement.ppt
bypayampayamy1
 
GINGIVAL-ENLARGEMENT
byPerio Files
 
Gingival enlargement
byKirthana MS
 
Gingival enlargement
byDr. Varsha Vishwakarma
 
Gingival Enlargement Periodontology Persentaty
byHome
 
GINGIVAL ENLARGEMENT Etiology and management
byPriyanka Pai
 
Lecture 4 Gingival Enlargement disorders
byahmedashraflol85
 
gingival enlarvhvhnvnhvnvvnvnvhnbgment.ppt
bySamanArshad11
 
Gingival Enlargementdental periodontal.pptx
byMohamedYElZahar
 
8)GINGIVAL ENLARGEMENT; a disease of the perodontium.pptx
byChukwuenyemBlessing
 
Gingival Enlargement in periodontics pptx
bySneha Banerjee
 
Gingival Enlargement.ppt
bypayampayamy1
 

More from Aishwarya Hajare

PPTX
Furcation involvement and management
byAishwarya Hajare
 
PPTX
local drug delivery in periodontics
byAishwarya Hajare
 
PPTX
Microbiology of periodontal diseases
byAishwarya Hajare
 
PPTX
Splinting in Periodontics
byAishwarya Hajare
 
PPTX
Trigeminal nerve and its dental implications
byAishwarya Hajare
 
PPTX
Lab investigations and interpretations in periodontics
byAishwarya Hajare
 
PPTX
Aggregatibacter actinomycetemcomitans
byAishwarya Hajare
 
PPTX
Sterilization and disinfection in dentistry
byAishwarya Hajare
 
PPTX
Local drug delivery system
byAishwarya Hajare
 
PPTX
Blood supplyand lymphatic drainage to oral cavity
byAishwarya Hajare
 
PPTX
Defense mechansism of gingiva
byAishwarya Hajare
 
PPTX
Neutrophil in health and disease
byAishwarya Hajare
 
PPT
Lymphatics of head and neck
byAishwarya Hajare
 
PPT
PRO AND PREBIOTICS
byAishwarya Hajare
 
PPTX
Bacterial growth & metabolism
byAishwarya Hajare
 
Furcation involvement and management
byAishwarya Hajare
 
local drug delivery in periodontics
byAishwarya Hajare
 
Microbiology of periodontal diseases
byAishwarya Hajare
 
Splinting in Periodontics
byAishwarya Hajare
 
Trigeminal nerve and its dental implications
byAishwarya Hajare
 
Lab investigations and interpretations in periodontics
byAishwarya Hajare
 
Aggregatibacter actinomycetemcomitans
byAishwarya Hajare
 
Sterilization and disinfection in dentistry
byAishwarya Hajare
 
Local drug delivery system
byAishwarya Hajare
 
Blood supplyand lymphatic drainage to oral cavity
byAishwarya Hajare
 
Defense mechansism of gingiva
byAishwarya Hajare
 
Neutrophil in health and disease
byAishwarya Hajare
 
Lymphatics of head and neck
byAishwarya Hajare
 
PRO AND PREBIOTICS
byAishwarya Hajare
 
Bacterial growth & metabolism
byAishwarya Hajare
 

Recently uploaded

PDF
Regal Best Kidney Multispecialty Hospital
bysekhardigitalmarketi
 
PPTX
MICROSPORIDIAL KERATITIS , CLINICAL FEATURES , TREATMENT
byDr Aarushi Choudhary
 
PPTX
OBSTRUCTED LABOR - Edward Mwansa.LGH.pptx
byedwardmwansa4
 
PPTX
Neurogenic oropharyngeal dysphagia in stroke 2025.pptx
byHeba El Saeid
 
PPTX
Swallowing & Swallowing Disorders SLP_1 lecture 4.pptx
byDr Zonera Khalid PT
 
PPTX
Historical background and development of profession of pharmacy pptx
byGulam Muheyuddeen
 
PDF
Dyes/ Stain Used In Ophthalmology - Clinical uses, Indication & Side effects....
bySamikshaRai22
 
PPTX
NEUROBIOLOGY OF AUTISM SPECTRUM DISORDER
byDr Hari Ram Sedai
 
PPTX
Management of TB in adults.pptx by Dr.Momen Mukhtar Abdalla MD,FCCP
bymomen14
 
PPTX
Disease, Spectrum of disease, Iceberg phenomenon of disease
byBindu Nepal
 
PPTX
Types of Communication Disorders SLP lecture 3.pptx
byDr Zonera Khalid PT
 
PPTX
Endotoxin Testing Using LAL: Practical GMP Approach
byshawkyabdo1
 
PDF
RETINAL VEIN OCCLUSION; CRVO & BRVO types, pathophysiology, diagnosis & manag...
bySamikshaRai22
 
PPTX
"SUPER FLU": TRUTH VS HYPE - WHAT CLINICIANS MUST KNOW
byArchitMehta11
 
PPTX
B SCAN . TECHNIQUES , PROBE POSITIONS , INDICATIONS
byDr Aarushi Choudhary
 
PPTX
Mental Health Awareness Campaign 2025 PPT.PPTX
byBirendra Bhatt
 
PPTX
Drying Pharmaceutical Engineering. pptxx
byShraddha Bandgar
 
PPTX
COGNITION IN DEPRESSION
byDr Hari Ram Sedai
 
PPTX
Pressure ulcer Internal KPIs results for July,2024.pptx
byprofyasser95
 
PPTX
Communication and utilization of research.pptx
byPreeti Kulshreshtha
 
Regal Best Kidney Multispecialty Hospital
bysekhardigitalmarketi
 
MICROSPORIDIAL KERATITIS , CLINICAL FEATURES , TREATMENT
byDr Aarushi Choudhary
 
OBSTRUCTED LABOR - Edward Mwansa.LGH.pptx
byedwardmwansa4
 
Neurogenic oropharyngeal dysphagia in stroke 2025.pptx
byHeba El Saeid
 
Swallowing & Swallowing Disorders SLP_1 lecture 4.pptx
byDr Zonera Khalid PT
 
Historical background and development of profession of pharmacy pptx
byGulam Muheyuddeen
 
Dyes/ Stain Used In Ophthalmology - Clinical uses, Indication & Side effects....
bySamikshaRai22
 
NEUROBIOLOGY OF AUTISM SPECTRUM DISORDER
byDr Hari Ram Sedai
 
Management of TB in adults.pptx by Dr.Momen Mukhtar Abdalla MD,FCCP
bymomen14
 
Disease, Spectrum of disease, Iceberg phenomenon of disease
byBindu Nepal
 
Types of Communication Disorders SLP lecture 3.pptx
byDr Zonera Khalid PT
 
Endotoxin Testing Using LAL: Practical GMP Approach
byshawkyabdo1
 
RETINAL VEIN OCCLUSION; CRVO & BRVO types, pathophysiology, diagnosis & manag...
bySamikshaRai22
 
"SUPER FLU": TRUTH VS HYPE - WHAT CLINICIANS MUST KNOW
byArchitMehta11
 
B SCAN . TECHNIQUES , PROBE POSITIONS , INDICATIONS
byDr Aarushi Choudhary
 
Mental Health Awareness Campaign 2025 PPT.PPTX
byBirendra Bhatt
 
Drying Pharmaceutical Engineering. pptxx
byShraddha Bandgar
 
COGNITION IN DEPRESSION
byDr Hari Ram Sedai
 
Pressure ulcer Internal KPIs results for July,2024.pptx
byprofyasser95
 
Communication and utilization of research.pptx
byPreeti Kulshreshtha
 

DRUG INDUCED GINGIVAL ENLARGMENT (DIGO)

  • 1.
  • 2.
    1. Introduction 2. Classificationof gingival enlargement 3. Indices for gingival enlargement 4. Drugs associated with gingival enlargement o Anticonvulsants o Immunosuppressants o Calcium Channel blockers o Miscellaneous 8. Prevalence of drugs causing gingival enlargement 9. Clinical manifestations and Histopathologic features 10. Pathogenesis of Drug induced gingival enlargement 11. Risk factors for Drug induced gingival enlargement 12. Management 13. References 2
  • 3.
    Coral PinkScalloped & Knifeedged Surface Texture StippledFirm & resilient consistency Size : Cellular + Intercellular + Vasculature Interdental Papilla Anterior – Pyramidal Posterior – Tent shaped Gingiva in health….. 3
  • 4.
    INCREASE IN SIZEOF GINGIVA INFLAMMATORY TYPE Increased cells Decreased fibers NON - INFLAMMATORY TYPE Increased fibers Decreased cells 4
  • 5.
    REASONS FOR INCREASEIN SIZE OF GINGIVA Accumulation of: Products of inflammation Increase in: Cellular + fibrous + ground substance 5
  • 6.
    Various terms usedpreviously Gingival Hyperplasia Gingival Hypertrophy Fibrous gingival Hyperplasia Gingival Overgrowth To denote excessive gingival proliferation secondary to drugs Gingival Enlargement Preferred term 6
  • 7.
    7 SEQUELAE OF GINGIVALOVERGROWTH Aesthetic changes Difficulty in maintaining good oral hygiene Clinical symptoms such as pain Speech disturbances Abnormal tooth movement Dental occlusion problem Enhanced risk of caries & periodontitis Brunnet et al 1996
  • 8.
  • 9.
    9 • Acute • Chronic Inflammatoryenlargement • Drug induced • Idiopathic Fibrotic enlargement • Fibrotic + InflammatoryCombined enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement OLDERCLASSIFICATION According to etiologic factors & pathologic changes
  • 10.
    10 • Acute • Chronic Inflammatoryenlargement Drug induced enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement MODIFIEDCLASSIFICATION According to etiology
  • 11.
    SHAFER’S CLASSIFICATION 11 Inflammatory gingival hyperplasia Noninflammatory (fibrous) gingival hyperplasia Combination of inflammatory and fibrous hyperplasia Shafer WG, Hine M, Levy B. Shafer’s textbook of oral pathology. Elsevier. New Delhi. 5th ed, 2006.
  • 12.
    12 BASED ON DISTRIBUTION Localized:Limited to the gingiva adjacent to single or group of teeth Generalized: Involving gingiva throughout the mouth BASED ON LOCATION Marginal: Confined to marginal gingiva Papillary: Confined to interdental papilla Diffuse: Involving the marginal, attached gingiva and papillae Discrete : An isolated sessile or pedunculated, tumour like enlargement
  • 13.
  • 14.
    • Kimbal etal, 1939 • Harris & Ewall, 1942 • Robinson et al, 1945 • Babcock and Nelson, 1964 • Angelopoulos & Goaz et al, 1972 • Conrad et al, 1974 • Barak et al, 1985 • Seymour et al, 1985 • Daley et al, 1986 • Friskopp & Klintman et al, 1986 • Mc Gaw index, 1987 • Kitaneara et al, 1990 • Miller and Damm index, 1992 • King et al, 1993 • Bokenkamp et al, 1994 • Miranda et al, 1998 • New index for DIGO (Ingles et al), 1999 • Modified Harris & Ewait index, (Prasad et al, 2002) VARIOUS INDICES USED TO MEASURE GINGIVAL ENLARGEMENT 14
  • 15.
    BASED ON CLINICALAPPEARANCE 1. Babcock and Nelson, 1964 GRADING OF GINGIVAL ENLARGEMENT 15 Mild No gingival enlargement or a minimal enlargement. Moderate Slight but definitive gingival enlargement, not interfering with function. Severe Gingival enlargement interfering with the function.
  • 16.
    2. Angelopolus &Goaz –1972 Nery et al (1995) modified by adding interproximal area. 16 Grade 0 No hyperplasia Grade 1 Hyperplasia covering cervical 3rd of anatomic crown Grade 2 Hyperplastic gingiva extending the middle 3rd of anatomic crown of teeth Grade 3 Hyperplastic gingiva covering > 2/3rd of crown of anterior tooth.
  • 17.
    17 Grade 0 Nosigns of inflammation Grade 1 GE confined to interdental papilla Grade 2 Enlargement involves papilla &marginal gingiva. Grade 3 Enlargement covers three quarters or more of crown. Grade 0 No signs of gingival enlargement. Grade I Enlargement confined to interdental papilla. Grade II Enlargement involves papilla and marginal gingiva Grade III Enlargement covers three quarter or more of the crown 3. Mc Gaw et al (1987) 4. Bokenkamp et al, 1994
  • 18.
    BASED ON HISTOPATHOLOGICALEXAMINATION Barak et al (1985) 18 Grade 1 Normal width of epithelium - 0.30 to 0.50 mm Grade 2 Slight hyperplasia - 0.50 to 1.5 mm Grade 3 moderate hyperplasia - 1.50 to 3.0 mm Grade 4 severe hyperplasia - 3 to 4 mm
  • 19.
    BASED ON ASSESSMENTOF PLASTER STUDY CASTS Seymour et al –1985 Included both gingival thickening and encroachment of gingival tissues on the adjacent crowns. 19 Grade 0 Normal Grade 1 Thickening from normal upto 2mm Grade 2 Thickening >2mm Criteria for assessing gingival thickness in a labio-lingual direction for a gingival unit. Criteria for assessing gingival encroachment on adjacent tooth surfaces for a gingival unit. (MGL = Mucogingival line).
  • 20.
    BASED ON PHOTOGRAPHICANALYSIS Ellis & Seymour, 1993 20 0 No encroachment of interdental papilla onto tooth surface. 1 Mild encroachment of interdental papilla, producing a blunted appearance to papilla tip. 2 Moderate encroachment, involving lateral spread of papilla across buccal tooth surface of less than one quarter tooth width. 3 Marked encroachment of papilla, i.e., more than 1/4 tooth width. Loss of normal papilla form.
  • 21.
    INDICES FOR DRUGINDUCED GINGIVAL ENLARGEMENT 21 0 No overgrowth 1 Early changes detectable, without encroachment on the tooth 2 Moderate changes, with increased enlargement of the interdental papillae and slight encroachment of the gingival tissues onto the tooth surfaces 3 Marked changes with obvious encroachment of the gingival tissues onto the tooth surfaces.
  • 22.
    Grade 0 Grade 1 NEWCLINICAL INDEX FOR DRUG INDUCED GINGIVAL OVERGROWTH 22 1 No overgrowth; firm adaptation of the attached gingiva to the underlying alveolar bone. 2 There is slight stippling; there is no granular appearance or a slightly granular appearance. 3 A knife-edged papilla is present toward the occlusal surface. 4 There is no increase in density or size of the gingiva. 1 Early overgrowth, as evidenced by an increase in density of the gingiva with marked stippling and granular appearance. 2 The tip of the papilla is rounded. 3 The probing depth is less than or equal to 3 mm.
  • 23.
    Grade 2 Grade 3 23 1Moderate overgrowth, manifested by an increase in the size of the papilla and/or rolled gingival margins. 2 The contour of the gingival margin is still concave or straight. 3 Gingival enlargement has a bucco-lingual dimension of up to 2 mm, measured from the tip of the papilla outward. 4 The probing depth is equal to or less than 6 mm. 5 The papilla is somewhat retractable. 1 Marked overgrowth, represented by encroachment of the gingiva onto the clinical crown. 2 The contour of the gingival margin is convex rather than concave. 3 Gingival enlargement has a bucco-lingual dimension of approximately 3 mm or more, measured from the tip of the papilla outward. 4 The probing depth is greater than 6 mm. 5 The papilla is clearly retractable.
  • 24.
    Grade 4 24 1 Severeovergrowth, characterized by a profound thickening of the gingiva 2 A large percentage of the clinical crown is covered. 3 Same as for grade 3: The papilla is retractable, the probing depth is greater than 6 mm, and the buccolingually dimension is approximately 3 mm.
  • 25.
    DRUGS ASSOCIATED WITHGINGIVAL ENLARGEMENT 25 Anticonvulsants Miscellaneous Calcium channel blockers Immunosuppressants
  • 26.
    PREVALENCE RATE 26 Phenytoin 50%Cyclosporine 30% Nifedipine 20% Drugs modifythe inflammatory and immunologic responses of the host to plaque Goldman et al Clinically & histologically gingival overgrowth induced by different drugs, are virtually indistinguishable. Wysocki et al 1983, Tyldesley & Rotter 1984
  • 27.
    ANTICONVULSANTS 27 HYDANTOINS SUCCINIMIDES VALPROICACID Ethotoin (Peganone®) Ethosuximide (Zarontin®) Depakene (Depakote®) Mephenytoin (Mesantoin®) Methsuximide (Celontin®) Phenytoin (Dilantin®) Phensuximide (Milontin®) Kimball 1939 - First to report gingival enlargement with chronic usage of Phenytoin. Children & Adolescents Adults Anterior region Posterior Region
  • 28.
    28 Uses Threshold plasma concentration Incidence Active metabolite Progression Epilepsy– generalized tonic-clonic seizures, partial seizures. 10-20µg/ml (Rees et al, 1993) 0 - 84.5%, Average 50% (Angelopoulo s et al) 5- parahydroxyp henyl-5- phenylhydant oin Onset – after one month of use. Trigeminal & related neuralgias ↑ prevalence in children (Dahllof & Modeer) Maximum severity reached: 12-18 months Cardiac arrhythmias Decreased rate observed: in the second year Adverse drug effects 1. Nausea, Vomitting, Epigastric pain & anorexia. 2. Nystgmus, Diplopia, Ataxia. 3. Gingival hyperplasia (common in children on prolonged use). 4. Peripheral neuropathy. 5. Endocrine – i) Hirsuitism, acne, coarsening of facial features ii) Hyperglycemia, iii)Osteomalacia, hypocalcaemia 6. Hypersensitivity reactions 7. Megaloblastic Anaemia 8. Teratogenicity PHENYTOIN
  • 29.
    29 Immunosuppressants Cyclosporin A Tacrolimus Cyclosporin –A First isolated in Switzerland – 1970, Jean Borel First case reported by - Rateitschak Pluss,1983 Suppress some humoral immunity (B lymphocytes) and to a much greater extent, cell-mediated immunity (T lymphocytes) such as allograft rejection, delayed hypersensitivity. Inhibits IL-2 synthesis and release.
  • 30.
    30 IMMUNOSUPPRESSANTS Uses Threshold plasma concentration Incidence Active metabolite Progression Immunosuppressantin transplant rejection (kidney, heart, liver transplant) > 400ng/ml 25% of renal transplant cases OL-17 Progressive enlargement occurs over several months Treatment of rheumatoid arthritis, psoriasis 38% of Cardiac transplants Reaches peak after one year of treatment Severe atopic dermatitis, chronic autoimmune urticaria 37% of Liver transplants Graft-versus Host reaction Adverse drug effects 1. Nephrotoxicity 2. Hepatotoxicity 3. Anorexia 4. Gum hypertrophy 5. Increased susceptibility to infections Friskopp & Klintmalm (1986)- Enlargement restricted to keratinized gingiva but can extend coronally. Absent in edentulous areas.
  • 31.
    CALCIUM CHANNEL BLOCKERS 31 Dihydropyridine derivatives Benzothiazinederivatives Phenylalkylamine derivatives Amlodipine (Lotrel®, Norvasc ®) Diltiazem (Cardizem®, Dilacor®, Tiazac®) Verapamil HCL (Calan®, Isoptin®, Verelan®) Felodipine (Plendil®) Nifedipine (Adalat®, Procardia ®) Nimodipine (Nimotop®) Lederman et al, 1984 - First to report gingival enlargement with chronic usage of Nifedipine
  • 32.
    32 Uses Pulmonary HypertensionRaynaud’s phenomena Threshold plasma concentration 800ng/ml Resulted in gingival overgrowth (rat model) Nishikawa et al. 1995 Incidence 15% - 84% Avg: 42.5% Severity Increases the risk of periodontal destruction in patients with diabetes mellitus type 2 Does not appear to affect edentulous areas, Nifedipine induced gingival enlargement is seen around implants. (Silverstein et al 1995) Adverse drug effects 1. Cardiac depression 2. Facial flushing 3. Dizziness 4. Headache 5. Edema 6. Gingival enlargement
  • 33.
  • 34.
    34 CLINICAL FEATURES OFDRUG INDUCED GINGIVAL ENLARGEMENT
  • 35.
    CLINICAL FEATURES OFDRUG INDUCED GINGIVAL ENLARGEMENT • Growth starts as: o A painless beadlike enlargement of the interdental papilla o Extends to facial & lingual gingival margins. • On progression: o Marginal & papillary enlargements unite o Develop into massive tissue fold covering large part of crown o Interfere with occlusion • When uncomplicated by inflammation: o Lesion is mulberry shaped o Firm and resilient o Pale pink o Minutely lobulated surface o No tendency to bleed 35
  • 36.
    • Enlargement characteristicallyappears to: o Project from beneath the gingival margin o From which it is separated by a linear groove. • Enlargement is usually generalized • More severe in maxillary & mandibular anterior regions. • Occurs in areas in which teeth are present & not in edentulous spaces. • Plaque control becomes difficult due to the enlargement Resulting Secondary inflammatory process (Further complicates the gingival overgrowth caused by the drug) 36
  • 37.
    Resultant enlargement Increase insize caused by the drug + plaque induced inflammation. • Drug-induced enlargement may occur in mouths: o With little or no plaque o May be absent in mouths with abundant deposits. • Enlargement is: o Chronic o Slowly increases in size. o When surgically removed, it recurs. o Spontaneous disappearance occurs within a few months after discontinuation of the drug. 37
  • 38.
    HISTOPATHOLOGY • Pronounced hyperplasiaof the connective tissue & epithelium. • Acanthosis of the epithelium. • Elongated rete pegs extending deep into the connective tissue. • Densely arranged collagen bundles. • Increase in the number of fibroblasts & new blood vessels. • Abundance of amorphous ground substance. Mariani et al 38
  • 39.
  • 40.
    DRUGS CLINICAL FEATURESHISTOPATHOLOGY PHENYTOIN • Granular or pebbly surface of affected tissues enlarged papillae extending facially &/or lingually. • Formation of pseudoclefts due to confluence of enlarged papillae (Hallmon & Rossmann) • Florid overgrowth of affected papillae. • Rare cases - observed in edentulous patients & beneath pontics of FPDs (McCord J, Sloan P, 1992) • Fibroblast to collagen ratio equal to that of normal gingiva from normal individuals. Florid overgrowth of affected papillae and presence of pseudoclefts resulting from overlapping of adjacent marginal gingiva and papillary confluence after long term Phenytoin use. 40 DRUGS CLINICAL FEATURES HISTOPATHOLOGY CYCLOSPORIN A • Affects children more frequently • Enlarged gingival tissues are soft • Extremely fragile • Red or bluish red • Bleed easily upon probing. • Restricted to keratinized gingiva only, so no interference with occlusion, mastication or speech. (Friskopp and Klintmalm, 1996) • More hyperemic than phenytoin induced enlargement. (Seymour & Jacobs, 1992) • Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells . NIFEDIPINE • Enlarged interdental papilla. • Lobulated /nodular morphology. • 10 fold increase in epithelial width. • Increase capillary vascularity • Slight perivascular inflammation. CYCLOSPORINE INDUCED GINGIVAL OVERGROWTH
  • 41.
    HISTOPATHOLOGY OF DRUG–INDUCEDGINGIVALENLARGEMENT PHENYTOIN NIFEDIPINE CYCLOSPORINA Fibroblast to collagen ratio in mature lesion is equal to that of normal gingiva from normal individuals Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells. • Ten fold increase in epithelial width. • Increased capillary vascularity and slight perivascular inflammation. 41
  • 42.
    42 PATHOGENESIS OF DRUG INDUCEDGINGIVAL ENLARGEMENT
  • 43.
    PATHOGENESIS OF DIGO 43 Pathogenesis Increasedcollagen synthesis Decreased collagen degradation - Extracellular pathway - Intracellular pathway Combination
  • 44.
    DRUG METABOLITES (Phenytoin,Nifedipine, Cyclosporin) Increased collagen production Increased extracellular matrix synthesis T- lymphocytes TH2 response IL-13, 1L4 Macrophages TGF-β CTGF FGF-2 PDGF 44 INCREASED COLLAGEN SYNTHESIS FIBROBLASTS Proliferation of highly active fibroblasts
  • 45.
    45 DECREASED COLLAGEN DEGRADATION Drugsassociated with gingival enlargement (Anticonvulsants, Immunosuppressants, CCB, others) Disturbance in calcium homeostasis Decreased influx of Ca2+ into fibroblast Decreased uptake of Ca2+ dependant folic acid by fibroblasts Decreased production of active collagenase Increased expression of TIMP Decreased MMP 1, 2 & 3 mediated collagen degradation
  • 46.
    Waxman et al,1970 Long term phenytoin therapy Low serum level of folic acid Drug metabolite reduces the absorption from GIT Blocks the transport across intestinal epithelium Decreased folate reductase Impaired maturation of epithelium Connective tissue susceptible to inflammation 46
  • 47.
    Decreased collagen phagocytosis Phenytoininduced Reduced α2β1 Integrin expression on fibroblasts Decreased adhesion of Type 1 Collagen with Fibroblast Decreased Endocytosis Decreased phagocytosis of Type 1 collagen Fibroblast Apoptosis Phenytoin induced Decreased Fibroblast apoptosis Contribute to fibrosis Increased number of fibroblasts Extracellular matrix accumulation Kantarci P A, 2007 47 INTRACELLULAR PATHWAY α 2β1 receptors Receptors UPARAP/ENDO 180 – One of the main receptors responsible for collagen phagocytosis. Not enough evidence to substantiate the role of this receptor.
  • 48.
    Joice et al:Phenytoin Induced Gingival overgrowth: A review of the cellular, molecular and inflammatory features 10.5402/2011/497850 Modification of immune cells by drug metabolites Imbalance in production of cytokines and other mediators Increased TGFβ1, FGF-2 and others TGFβ1 Increases synthesis and deposit of collagen. Regulation of TIMP. Reduction of collagen phagocytosis. Myofibroblasts are associated with later stages of tissue turnover. 48
  • 49.
    49 RISK FACTORS FORDRUG INDUCED GINGIVAL ENLARGEMENT
  • 50.
    RISK FACTORS FORDRUG INDUCED GINGIVAL ENLARGEMENT RISK FACTORS 1. Age 2. Genetic factors 3. Pharmacokinetic variables 4. Alterations in the gingival connective tissue 5. Drug induced action on growth factors. UNIFYING HYPOTHESIS Vogel et al discussed first the possible mechanism of pathogenesis that grouped several current hypothesis together. DISSIMILAR DRUGS - SIMILAR EFFECTS Action on Ca2+ & Na+ influx Link between dissimilar drugs causing gingival enlargement 50
  • 51.
    51 AGE Fibroblasts in areasof Inflamed gingival tissues Androgen (Testosterone) 5 α- Dihydrotestosterone (5α DHT) Biologically active Stimulation of biosynthetic activity in subpopulation of fibroblasts Increased collagen production Children/Adolescent Increased production of androgen (testosterone) Sooriyamoorthy M, Gower D, Eley BM. Androgen metabolism in gingival hyperplasia induced by Nifedipine and Cyclosporin. JOP. 1990;25:25-30
  • 52.
    52 GENETIC PREDISPOSITION PHENYTOIN/CYCLOSPORINE/CCB Altered metabolismof drug Threshold concentration of drug/metabolite Disturbance in calcium homeostasis Decreased Folate Reductase Gingival fibroblasts are activated Decreased collagen breakdown Cytochrome P450 Genotype C807
  • 53.
    53 PHARMACOKINETIC VARIABLES Systemic administrationof drug Local sequestration Increased concentration in saliva/GCF Threshold concentration Altered fibroblast activity Concomitant Medication: Higher Incidence, Severity & Recurrence rate Phenytoin + Cyclosporin Bokenkamp 1994 Margiotta 1996 Prednisolone & Azathioprine - Combined immunosuppressant action with Phenytoin, Cyclosporin & Calcium channel blockers Degree of salivary Phenytoin & gingival overgrowth Babcock & Nelson1964 Cyclosporin concentration in stimulated saliva & extent of gingival overgrowth Mc Gaw et al 1987 Hefti et al 1994 Assumption: Serum concentration of active drug > gingival enlargement to occur. Threshold differs between: o Individuals o Drug to drug Seymour,1988, 2000 Daley et al1986 Patients exhibiting gingival overgrowth Nifedipine & Amlodipine Conclusions: 1. Can be detected in GCF 2. Significant sequestration of drug Ellis et al. 1992 Seymour et al. 1994 Direct relationship
  • 54.
    54 ALTERATION IN CONNECTIVETISSUE METABOLISM HOMEOSTATIC BALANCE Collagen production Collagen degradation ALTERED METABOLISM Fibroblast heterogeneity Hyperactivity Increased TIMP (Tipton et al, 1991) Decreased/abnormal Collagenase Increased collagen production (Goultchin & Shoskan 1980) Decreased collagen breakdown Acanthosis & accumulation of non collagenous extracellular substances In addition deficiency of Cathepsin B and L together with increased levels of Hexose amine, Hyaluronic acid and total protein content.
  • 55.
    55 . PHENYTOIN Responders: Up-regulation ofEGF receptor metabolism Non responders: Down-regulation of EGF receptor metabolism Modeer et al 1990 d PDGF secretion from macrophages Dill et al. 1993 Abnormal response to plaque induced inflammatory changes DRUG-INDUCEDACTIONON GROWTH FACTORS
  • 56.
  • 57.
    MANAGEMENT OF GINGIVALENLARGEMENT 57 NON SURGICAL 1. Scaling and Root planing 2. Drug Substitution 3. Antimicrobials 4. Supplements SURGICAL 1. Gingivoplasty 2. Gingivectomy 3. Periodontal flap surgery
  • 58.
    58 Mouth wash Chlorhexidine Gluconate– 0.2 % Metronidazole Usage is controversial Increases drug metabolites of Cyclosporin in blood. Adverse drug effects of Cyclosporin Seen Azithromycin Mechanism of Action:  High intracellular accumulation (Azithromycin metabolites): o Endogenous defense cells o Tissues affected by inflammatory changes  Increase phagocytosis of collagen fibres Counter acts Decreasing accumulation of extracellular matrix ANTIBIOTICS Dannewitz B, Proliferation of the gingiva: etiology, risk factors and treatment modalities for gingival enlargement. Perio 2007;4(2):83-92
  • 59.
    59 SUBSTITUTE FOR NIFEDIPINE SUBSTITUTE FOR CYCLOSPORINA SUBSTITUTE FOR PHENYTOIN Isradipine 20 mg BD Tacrolimus (0.15 - 0.20/kg/d) Phenobarbital 60 mg TDS ACE Inhibitors - Captopril 12.5 - 50 mg BD - Enalapril (2.5 - 20 mg OD) Rapamycin Primidone 100 mg TDS Carbamazepine 200 – 400 mg TDS Valproic acid 200 – 500 mg TDS
  • 60.
    60 No sufficient dataexists to indicate folic acid therapy is beneficial in Phenytoin induced Gingival enlargement PHENYTOIN INDUCED GINGIVAL ENLARGEMENT Therapeutic benefits Inove & Harrison, Prasad et al No therapeutic benefits Brown et al, Majota et al Folic acid therapy
  • 61.
  • 62.
    62 1. Text bookof Periodontology by Carranza FA. 10th edition 2007. 2. Textbook of Periodontics, Medicine, surgery and Implants by Rose, Mealey, Genco. 2004. 3. Paulo M, Camargo, Philip R, Melnick, Flavia M, Pirih, Takei. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontology 2000, Vol. 27, 2001, 131–138. 4. William W, Hallmon, Jeffrey A, Rossmann. The role of drugs in the pathogenesis of gingival overgrowth: A collective review of current concepts. Periodontology 2000, Vol. 21, 1999, 176-196. 5. Michelle L, Moffitt, David E, Bencivenni, Robert E Cohen. Drug-Induced Gingival Enlargement: An Overview. Compend; CDE 2; 2013, 34: 5.
  • 63.
    63 6. Brown RS,Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. On the mechanism of DIGH. Oral Pathol Med. 1991; 20:201-9. 7. Nyska A, M. Shemesh, H Tal, Dayan D. Gingival Hyperplasia Induced by Calcium Channel Blockers: Mode of Action. Medical Hypothesis. 1994; 43:115-118. 8. Christina Popova, Antoaneta Mlachkova. Surgical approach to drug - induced 9. gingival enlargement in renal transplant patients: Case report. J of IMAB, 2007, vol. 13, book 2. 10. Arnold D Steinberg. Clinical management of phenytoin-induced gingival overgrowth in handicapped children. Pediatric dentistry. Volume 3, Special Issue. 11. Chae HJ, Ha MS, Yun DH, Chung HT. Mechanism of Cyclosporine-induced Overgrowth in Gingiva. J Dent Res85(6):515-519, 2006.
  • 64.
  • 65.